Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.2
Commitments and Contingencies (Details Narrative)
3 Months Ended 9 Months Ended
Aug. 12, 2020
USD ($)
shares
Aug. 01, 2020
USD ($)
shares
Jul. 15, 2020
USD ($)
shares
Feb. 18, 2020
USD ($)
Sep. 12, 2018
USD ($)
Aug. 20, 2018
USD ($)
Apr. 05, 2018
USD ($)
Apr. 05, 2018
EUR (€)
Apr. 02, 2018
Mar. 22, 2018
USD ($)
Sep. 14, 2015
USD ($)
Dec. 24, 2013
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Research and development costs                         $ 799,420   $ 570,601 $ 1,012,038 $ 699,038  
Stock options granted to purchase common stock, issued | shares                               900,000    
Dr. John Kovach [Member]                                    
Annual salary                         15,000   15,000 $ 45,000 45,000  
NDA Consulting Corp [Member]                                    
Agreement term                       1 year            
Consulting and advisory fee                       $ 4,000 4,000   4,000 12,000 12,000  
Clinical Trial Research Agreement [Member]                                    
Research and development costs                               81,101    
Clinical Trial Research Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                    
Payments for clinical trial                         10,643   9,996 36,008 23,249  
Aggregate commitments expected                         621,000     621,000    
Collaboration Agreement [Member]                                    
Research and development costs                         $ 87,471 130,882  
Advance amount related to milestone payment                         0   87,471 43,411 87,471  
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member]                                    
Research and development costs                         30,000   30,000 90,000 70,000  
Consulting and advisory fee                     $ 10,000              
Collaboration Agreement [Member] | Grupo Espanol de Investigacion en Sarcomas [Member]                                    
Advance amount related to milestone payment       $ 43,411                            
Aggregate commitments expected                         4,428,000     4,428,000    
Clinical Trial Agreement [Member]                                    
Aggregate commitments expected                         5,049,000     $ 5,049,000    
Aggregate commitments expected, description                               The Company's aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $5,049,000 as of September 30, 2020, consisting of approximately $4,428,000 relating to the GEIS clinical trial and approximately $621,000 relating to the Moffit clinical trial, which are expected to be incurred over the next five years through June 30, 2025.    
Work Order Agreement [Member]                                    
Research and development costs                               $ 75,885    
Aggregate commitments expected                         875,000     875,000    
Work Order Agreement [Member] | Theradex Systems, Inc [Member]                                    
Research and development costs         $ 954,000               917   3,190 12,393 51,683  
Payment expected dividend for pass-through costs, description         The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019. At the current rate of accrual, the trial would be completed over a period of four years from its initiation, with the final analysis and reporting expected by July 2023. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.                          
Other Clinical Agreements [Member]                                    
Research and development costs                         41,625     41,625    
Aggregate commitments expected                         258,000     258,000    
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member]                                    
Milestone payments                   $ 1,750,000                
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member]                                    
Milestone payments                   $ 6,500,000                
Consulting Agreement with Liberi Life Consultancy BV [Member]                                    
Agreement term                 2 years                  
Payment of a fixed, one-time retainer             $ 18,348                      
Net payments of sales of products or licensing activities, percentage             2.50% 2.50%                    
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member]                                    
Payment of a fixed, one-time retainer | €               € 15,000                    
Consulting Agreement [Member]                                    
Amortizing the retainer payment                         0   2,294 2,294 6,882  
Unamortized balance of the retainer payment                                   $ 9,174
Exclusive License Agreement [Member]                                    
Amount charges to operations                         6,301   $ 31,301 $ 18,699 $ 74,368  
Royalties description                               The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.    
Exclusive License Agreement [Member] | First Four Years [Member]                                    
Minimum payments for royalties                               $ 50,000    
Exclusive License Agreement [Member] | Five Years and Thereafter [Member]                                    
Minimum payments for royalties                               100,000    
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member]                                    
Non-refundable license issue fee           $ 25,000                        
Annual license maintenance fee           25,000                        
Payments on non-refundable milestone           $ 1,897,000                        
Percentage of milestone           40.00%                        
Employment Agreement [Member] | Dr. John Kovach [Member]                                    
Annual salary     $ 250,000                              
Employment Agreement [Member] | Eric Forman [Member]                                    
Annual salary     $ 120,000                              
Stock options granted to purchase common stock, issued | shares     350,000                              
Employment Agreement [Member] | Dr. James Miser [Member]                                    
Annual salary   $ 150,000                                
Stock options description   Dr. Miser was granted options for 500,000 shares of the Company's common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $1.19 per share, which was equal to the closing price of the Company's common stock on the effective date of the employment agreement. The options vested as to 25% on the effective date, and will vest 25% on each of the first, second and third anniversaries of the effective date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($1.1453 per share), of which $143,163 was attributable to the stock options fully-vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options will be charged to operations ratably from August 1, 2020 through August 1, 2023. During the three months and nine months ended September 30, 2020, the Company recorded a charge to operations of $166,697 with respect to these stock options.                                
Charges for salary                         25,000     25,000    
Stock options granted to purchase common stock, issued | shares   500,000                                
Employment Agreement [Member] | Mr. Weingarten [Member]                                    
Annual salary $ 120,000                                  
Stock options description On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted options for 350,000 shares of the Company's common stock. The options can be exercised on a cashless basis. The options have a term of 5 years and an exercise price of $1.19 per share, which was equal to the closing price of our common stock on the grant date. The options vested as to 25% on August 12, 2020, and will vest 25% on each of the first, second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($1.1453 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options will be charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months and nine months ended September 30, 2020, the Company recorded a charge to operations of $113,667, with respect to these stock options.                                  
Charges for salary                         $ 16,452     $ 16,452    
Stock options granted to purchase common stock, issued | shares 350,000                                  
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member]                                    
Percentage of proceeds agree to pay under agreement 5.00%                                  
Maximum amount received under agreement $ 250,000